Michael Sand
YOU?
Author Swipe
View article: Whole-miRNome sequencing: a panel for the targeted sequencing of all human miRNA genes
Whole-miRNome sequencing: a panel for the targeted sequencing of all human miRNA genes Open
Interest in the genetic variation of noncoding genomic elements, including microRNAs (miRNAs), is growing, and several mutations in miRNA genes implicated in human diseases, including cancer, have already been detected. However, the lack o…
View article: Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program
Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program Open
The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) project assesses a large sample of individuals at clinical high-risk for developing psychosis (CHR) and community controls. Subjects are enrolled in 43 sites across 5 contine…
View article: Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample Open
Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairmen…
View article: Whole-miRNome sequencing (WMS) - a panel for targeted sequencing of all human miRNA genes
Whole-miRNome sequencing (WMS) - a panel for targeted sequencing of all human miRNA genes Open
There is a growing interest in the genetic variation of noncoding genomic elements, including miRNAs, and several mutations in miRNA genes implicated in human diseases, including cancer, have already been detected. However, the lack of ded…
View article: A new era for schizophrenia drug development – Lessons for the future
A new era for schizophrenia drug development – Lessons for the future Open
For many patients and their treating clinicians, the pharmacological management of psychotic symptoms centres on trying to find a regime that balances efficacy and quality of life-impairing side effects associated with dopamine antagonism.…
View article: Assessing the Unmet Clinical Need and Opportunity for Digital Therapeutic Intervention in Schizophrenia: Perspective From People With Schizophrenia
Assessing the Unmet Clinical Need and Opportunity for Digital Therapeutic Intervention in Schizophrenia: Perspective From People With Schizophrenia Open
Introduction Recent research has highlighted the increasing ubiquity of smartphone ownership as well as the feasibility of digital interventions within schizophrenia. Digital therapeutics, a subset of digital interventions, have establishe…
View article: AI-Based Adherence Prediction for Patients: Leveraging a Mobile Application to Improve Clinical Trials
AI-Based Adherence Prediction for Patients: Leveraging a Mobile Application to Improve Clinical Trials Open
Introduction Medication nonadherence is a public health concern and can impact clinical trial data quality. Traditional compliance collection (pill counts, diaries) can be unreliable in central nervous system trials. As such, strategies su…
View article: Table S1- S2 from Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma
Table S1- S2 from Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma Open
Information of MCC (Table S1) and non MCC cell lines (Table S2) used in the experiments.
View article: Table S3- S6 from Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma
Table S3- S6 from Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma Open
Clinical data of MCC patients from Graz (Table S3), Seattle (Table S4), Essen (Table S5) and Melbourne (Table S6).
View article: Table S1- S2 from Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma
Table S1- S2 from Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma Open
Information of MCC (Table S1) and non MCC cell lines (Table S2) used in the experiments.
View article: Figure S1-S6 from Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma
Figure S1-S6 from Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma Open
Fig. S1: miR-375 demonstrates by far the highest ratio of extracellular to cellular miRNA; Fig. S2: Circulating cell-free miR-375 in serum discriminates healthy donors from MCC patients with tumor burden; Fig. S3: cf miR-375 serum level pe…
View article: Data from Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma
Data from Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma Open
Purpose:Merkel cell carcinoma (MCC) is an aggressive skin cancer with neuroendocrine differentiation. There is an unmet need for MCC-specific blood-based surrogate biomarkers of tumor burden; circulating cell-free miRNA may serve this purp…
View article: Figure S1-S6 from Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma
Figure S1-S6 from Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma Open
Fig. S1: miR-375 demonstrates by far the highest ratio of extracellular to cellular miRNA; Fig. S2: Circulating cell-free miR-375 in serum discriminates healthy donors from MCC patients with tumor burden; Fig. S3: cf miR-375 serum level pe…
View article: Table S3- S6 from Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma
Table S3- S6 from Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma Open
Clinical data of MCC patients from Graz (Table S3), Seattle (Table S4), Essen (Table S5) and Melbourne (Table S6).
View article: Data from Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma
Data from Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma Open
Purpose:Merkel cell carcinoma (MCC) is an aggressive skin cancer with neuroendocrine differentiation. There is an unmet need for MCC-specific blood-based surrogate biomarkers of tumor burden; circulating cell-free miRNA may serve this purp…
View article: Profile of Basal Cell Carcinoma Mutations and Copy Number Alterations - Focus on Gene-Associated Noncoding Variants
Profile of Basal Cell Carcinoma Mutations and Copy Number Alterations - Focus on Gene-Associated Noncoding Variants Open
Basal cell carcinoma (BCC) of the skin is the most common cancer in humans, characterized by the highest mutation rate among cancers, and is mostly driven by mutations in genes involved in the hedgehog pathway. To date, almost all BCC gene…
View article: The Role of Circular RNAs in Keratinocyte Carcinomas
The Role of Circular RNAs in Keratinocyte Carcinomas Open
Keratinocyte carcinomas (KC) include basal cell carcinomas (BCC) and cutaneous squamous cell carcinomas (cSCC) and represents the most common cancer in Europe and North America. Both entities are characterized by a very high mutational bur…
View article: Profile of basal cell carcinoma mutations and copy number alterations - focus on gene-associated noncoding variants
Profile of basal cell carcinoma mutations and copy number alterations - focus on gene-associated noncoding variants Open
Basal cell carcinoma (BCC) of the skin is the most common cancer in humans, characterized by the highest mutation rate among cancers, and is mostly driven by mutations in genes involved in the hedgehog pathway. To date, almost all BCC gene…
View article: Correction to: Comparison of the Skin Cancer Quality of Life Impact Tool and the Skin Cancer Index Questionnaire in Measurement of Health-Related Quality of Life and the Effect of Patient Education Brochures in Patients with Actinic Keratosis, Non-melanoma Skin Cancer, and Cutaneous Melanoma
Correction to: Comparison of the Skin Cancer Quality of Life Impact Tool and the Skin Cancer Index Questionnaire in Measurement of Health-Related Quality of Life and the Effect of Patient Education Brochures in Patients with Actinic Keratosis, Non-melanoma Skin Cancer, and Cutaneous Melanoma Open
A correction to this paper has been published: https://doi.org/10.1007/s13555-021-00540-w
View article: Comparison of the Skin Cancer Quality of Life Impact Tool and the Skin Cancer Index Questionnaire in Measurement of Health-Related Quality of Life and the Effect of Patient Education Brochures in Patients with Actinic Keratosis, Non-melanoma Skin Cancer, and Cutaneous Melanoma
Comparison of the Skin Cancer Quality of Life Impact Tool and the Skin Cancer Index Questionnaire in Measurement of Health-Related Quality of Life and the Effect of Patient Education Brochures in Patients with Actinic Keratosis, Non-melanoma Skin Cancer, and Cutaneous Melanoma Open
Impaired health-related quality of life is correlated with a patient with skin cancer's age, gender, and the location of the lesion. Physicians should consider these factors in clinical practice and advocate the use of patient education br…